More men with advanced prostate cancer could be successfully treated with precision drug olaparib 15 Jul 2024 Scientists have discovered a genetic aberration found in some prostate cancers that could allow more men to be successfully treated with targeted drug olaparib Find out more Show/Hide
ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer 05 Apr 2023 The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer. Find out more Show/Hide
ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer 10 Nov 2022 The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022